CD7 Antibody Antagonists for Therapeutic Applications

USPTO published patent application US20260098089A1 covering CD7 (Cluster of Differentiation 7) antibody antagonists and fragments for therapeutic applications. The application, filed September 8, 2025 under application number 19322242, includes methods of treatment, uses, and combinations involving these antagonists. CPC classifications indicate applications in immunological disorders and oncology (A61P 35/02). Patent applications establish priority dates and are publicly viewable but do not yet grant enforceable rights.

For pharmaceutical companies and biotechnology firms developing CD7-targeted therapeutics, this published application signals active patent prosecution in this space and potential freedom-to-operate considerations. Inventors include E-Chiang Lee, Gwenoline Borhis, Cassandra Van Krinks, Lucy Hepburn, Luke Bayliss, and Miha Kosmac. Competitors should monitor prosecution to assess claim scope and potential licensing needs.